David A. Siegel Entrada Therapeutics, Inc. Transaction History
Two Sigma Advisers, LP
- $47 Billion
- Q3 2025
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 51,500 shares of TRDA stock, worth $436,205. This represents 0.0% of its overall portfolio holdings.
Number of Shares
51,500Holding current value
$436,205% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding TRDA
# of Institutions
118Shares Held
27.9MCall Options Held
13.7KPut Options Held
14K-
Baker Bros. Advisors LP New York, NY4.87MShares$41.2 Million0.23% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.38MShares$37.1 Million56.82% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.26MShares$36.1 Million16.56% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$14.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.6MShares$13.6 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $266M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...